Regarding CSMD2 and relapse-free survival (RFS), a significant negative association was found in patients with BRCA, ESCC, KIRP, PAAD, and STAD patients (Figures 3J–N). This evidence concerns the gene CSMD2 and gastric adenocarcinoma.